Under the proposed deal, Sanofi could acquire about 20% stake in ASCL, subject to approval from the FIPB (Foreign Investment Promotion Board). Competition Commission of India has already given its nod for the proposed stake buy by French pharmaceutical major.
"We are aiming to have 50 sugar clinics by the end of current year and take it further to more than 200 by 2016," SnagIta Reddy, chairperson at Apollo Sugar said here on Tuesday.
According to Reddy, who is also joint managing director at Apollo Hospitals pointed out that the cost for each clinic could entail a cost of about Rs 30-60 lakh.
In India alone, 65 million people are affected from diabetes while 77.2 million people are in the pre diabetic stage. Globally this non communicable disease has affected about 382 million lives. India's pie in diabetic patients is expected to swell upto 109 million by 2035.
Reddy claimed that the sugar clinics would be cost effective for the diabetics and provide a 360 degree lifestyle management program.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)